脂肪营养不良
脂肪组织
抗逆转录病毒疗法
腹部脂肪
人类免疫缺陷病毒(HIV)
医学
生长激素
内科学
激素
内分泌学
泌尿科
体重
病毒载量
免疫学
作者
Qing He,Ellen S. Engelson,Jeanine Albu,Steven B. Heymsfield,Donald P. Kotler
标识
DOI:10.1152/japplphysiol.00845.2002
摘要
Lipodystrophy with increased intra-abdominal fat in human immunodeficiency virus (HIV) infection is common in the era of highly active antiretroviral therapy. It contributes to the metabolic derangements, as it does in non-HIV-related conditions. Growth hormone administration reduces intra-abdominal fat content. This study compared the relative changes in omental-mesenteric (OMAT) and retroperitoneal adipose tissues (RPAT) during therapy with recombinant human growth hormone (rhGH) in HIV-associated lipodystrophy. Of 30 subjects who began rhGH therapy (6 mg/day), 25 completed 12 wk and 19 completed 24 wk. Fourteen subjects were followed for an additional 12 wk. Volumes of OMAT and RPAT were calculated from total body MRI scans and compared by paired t-tests. Both OMAT and RPAT significantly decreased after 12 and 24 wk of rhGH treatment ( P < 0.001), but the reduction was more pronounced in OMAT than in RPAT ( P< 0.001). Both OMAT and RPAT increased significantly ( P < 0.001) after therapy was discontinued, but OMAT increased significantly more than did RPAT (122 vs. 37%, P < 0.001). There is preferential loss and regain of OMAT, compared with RPAT, in subjects with HIV-associated lipodystrophy undergoing growth hormone treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI